ANMAT Disposición 5146/2026

ANMAT Disposición 5146/2026 is an Argentine pharmaceutical regulation issued by the National Administration of Drugs, Foods and Medical Devices (ANMAT). It updates the technical criteria for manufacturing large-volume parenteral solutions (LVPs) using a closed manufacturing system. Published in Argentina's Official Gazette on August 18, 2026, the regulation amends Article 1 of ANMAT Disposición E 11857/2017 and introduces a more specific definition of closed-system manufacturing.

What does ANMAT Disposición 5146/2026 require?

The central change concerns the configuration of the manufacturing process. Under the revised definition, primary container formation, filling, and sealing must be performed in a manner that prevents the product from contacting the surrounding environment during critical manufacturing stages. This protected condition must be maintained until terminal sterilization.

The regulation expressly excludes processes in which the primary container has already been formed before filling from the definition of a closed manufacturing system.

Consequently, performing filling operations in a controlled environment or sealing a previously formed container does not, by itself, satisfy the revised definition. The requirement focuses on the integration of container formation, filling, and sealing while preventing environmental exposure during critical operations.

Which pharmaceutical products are covered?

The regulation specifically addresses large-volume parenteral solutions, as defined by the applicable Argentine regulatory framework.

These products are aqueous, sterile, nonpyrogenic solutions packaged in a single container with a capacity of 100 mL or more and subjected to terminal sterilization.

The category includes solutions intended for intravenous administration, irrigation, and peritoneal dialysis. Products of biological origin are excluded from this regulatory definition.

These criteria should not be automatically extended to small-volume parenterals or every type of sterile injectable preparation. The scope of the regulation is defined by the specific pharmaceutical category and manufacturing conditions addressed in the Argentine provisions.

How does closed-system manufacturing differ from quality control?

Closed-system manufacturing concerns the design and operation of the production process, particularly the prevention of product exposure to the external environment.

Pharmaceutical quality control involves testing and evaluating the physical, chemical, and microbiological characteristics of the finished preparation.

Relevant quality attributes for parenteral solutions include:

• Sterility: compliance with applicable microbiological requirements.
• Bacterial endotoxins: control of contaminants associated with pyrogenic reactions.
• Visible and subvisible particles: assessment of particulate contamination using appropriate pharmacopoeial methods.
• Container closure integrity: verification that the packaging system maintains the necessary protective barrier.
• Stability: evidence that critical product quality attributes remain within specifications throughout the shelf life.

ANMAT Disposición 5146/2026 does not itself establish new numerical acceptance limits for subvisible particulate matter. Its principal purpose is to define the manufacturing conditions required for a closed system. Particle testing and other quality assessments remain governed by the applicable pharmacopoeial and regulatory requirements.

What are the implementation and compliance requirements?

The regulation allows marketing authorization holders using manufacturing technologies that differ from the newly defined system to request approval of an adaptation plan from ANMAT.

Such a plan must describe the measures required to meet the established conditions, subject to the timelines and requirements determined by the regulatory authority.

The regulation provides for entry into force 180 calendar days after its publication in the Official Gazette on August 18, 2026.

For manufacturing, engineering, quality assurance, and regulatory affairs teams, compliance assessment involves reviewing production-line configuration, the sequence of critical operations, environmental exposure risks, and technical documentation supporting the manufacturing process.

Frequently asked questions about ANMAT Disposición 5146/2026

Does Disposición 5146/2026 require closed-system manufacturing?

Yes. The regulation maintains the closed-system manufacturing requirement for large-volume parenteral solutions and provides a revised technical definition of the manufacturing process.

Can a production line using preformed containers meet the revised definition?

No. The regulation expressly excludes processes using previously formed primary containers from its definition of a closed manufacturing system.

Does the regulation introduce new subvisible particle limits?

No. Its primary focus is the manufacturing process rather than numerical particulate contamination limits. Applicable pharmacopoeial quality requirements remain relevant to the finished pharmaceutical product.